Stem Cell Clinic

Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Cryo-Save Group N.V. (Euronext: CRYO, `Cryo-Save`, or `the Group`), the leading international stem cell storage brand and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2011.

Financial highlights

Revenue up 4% to 41.9 million (2010: 40.4 million) Operating expenses before depreciation and amortisation increased with 1.6 million mainly due to further investments in Cryo-Lip (0.8 million) and acquisition impact (0.7 million) EBITDA*: 6.3 million (2010: 7.3 million) EBITA**: 4.5 million (2010: 5.8 million) Operating profit: 2.9 million (2010: 4.5 million) Profit before taxation: 3.0 million (2010: 3.9 million) Net profit: 2.3 million (2010: 2.6 million) Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents) Robust net cash from operating activities 6.2 million (2010: 2.8 million) Solid cash position of 7.0 million as at 31 December 2011 (2010: 6.0 million) Dividend per share of 0.08, up 14% (2010: 0.07)

* EBITDA is defined as Earnings Before Interest, Taxation Depreciation and Amortisation ** EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets

Operational highlights

39,900 new samples stored in 2011, up 4% compared to previous year (2010: 38,300). Of these, 25,200 were new cord blood samples and 14,700 new cord tissue samples 204,000 samples have been stored in total at 31 December 2011 67% of new customers opt for combined service of cord blood and cord tissue storage Acquisition of Serbian distributor Life R.F. for 2.3 million in cash and 30,000 Cryo-Save shares Cryo-Save USA founded, to commercialize and develop the Cryo-Lip service in North America Cryo-Save South Africa joint venture established and stem cell processing and storage laboratory opened in Cape Town together with John Daniel Holdings and Lazaron Biotechnologies A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke University in the US with her own cord blood stem cells, which were stored and released by Cryo-Save

Outlook

Revenue increased with 1.4 million to 41.9 million, largely due to increased sales volumes in several countries, acquisitions and increased number of new cord tissue samples, partly offset by lower business volume in mainly Southern Europe. The impact of the economic crisis also resulted in a significantly lower number of births in almost all countries. An increasing demand for discounts on the service fee and instalment plans to facilitate the payment of the service fee has been another factor affecting revenue growth.

The gross profit margin decreased with 1% to 66.6%, among others due to an increased demand for higher reimbursements of the collection of the umbilical cord blood and cord tissue in the hospitals. The gross profit margin remained at the same level compared to the second half of 2010 (66.5%).

Operational expenses increased with 1.6 million due to incremental expenses related to Cryo-Lip (0.8 million), and the impact of the acquisitions of Tissue Bank Cryo Center Bulgaria AD ("TBCCB") and Life R.F. doo, Serbia ("Life") (0.7 million).

Excerpt from:
Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Hero Dog Receives Stem Cell Therapy

Stem Cell Therapy Helping Heroic Dogs Recover

News4's Darcy Spencer explains how a breakthrough treatment is helping search and rescue dogs like Red recover after years of working in disaster zones.

A breakthrough treatment is helping area search-and-rescue dogs that played key roles on Sept. 11, 2001, and during other disasters.

Red's first assignment as a search, rescue and recovery dog was at the Pentagon following the 9/11 attacks. Years of rescue work and a 12-foot fall from a ladder have taken a toll. Arthritis forced Red into retirement in July and turned her into a couch potato.

The 12-year-old black lab received a breakthrough stem cell treatment today that will ease her pain and give her more mobility.

Her veterinarian, Dr. John Herrity, of the Burke Animal Clinic, has done more than two dozen of the stem cell operations developed by Medivet America, which also donated the cost of the procedure.

The treatment won't bring Red back out of retirement, but it is expected to put spring back in her step within a couple of months.

Two other 9/11 search-and-rescued dogs have been treated with stem cell therapy and are back to their normal activities.

Link:
Hero Dog Receives Stem Cell Therapy

9/11 Search And Rescue Dog Gets Stem Cell Treatment

BURKE, Va. (WUSA) -- Red, a black lab from Annapolis, has spent the last ten years as a search and rescue dog. Her missions have included Hurricane Katrina, the La Plata tornadoes, and the Pentagon after 9/11.

"The search and rescue dogs at the Pentagon are credited with finding 70% of the human remains," said Heather Roche, Red's owner and handler. "That helped a whole lot of those families actually get closure."

At just under two years old, 9/11 was Red's first search. Today, she's one of the last 9/11 search and rescue dogs still alive. She retired last July due to severe arthritis.

"The last few months, she would like to be a couch potato but she can't even get on the couch any more," said Roche. "It would be nice if she could do those kinds of things that she misses."

Roche brought Red to the Burke Animal Clinic for stem cell regenerative therapy compliments of MediVet America, the company that developed the in-clinic stem cell technology.

"This is a small something that we can give back as a way of saying thanks for what you guys have done for us," said Dr. John Herrity at the Burke Animal Clinic. "We are just taking fat from Red's side and then we are going to spin it down, process it, extract the stem cells from there."

Red received her first injection just a few hours after she woke up from surgery. The rest of her extracted stem cells will be stored free of charge for use in follow-up treatments.

"We've done about 28 dogs and of those dogs we've had about 75-80% of them doing very well," said Dr. Herrity.

Two other 9/11 dogs that recently received the same stem cell therapy are able to run, climb, and play again. Dr. Herrity's own dog, Bradley, is living proof that the treatment works. Bradley received the same stem cell treatment about one year ago and he's made great progress.

"Hopefully in about 2-3 months, she will be more comfortable, moving around, wanting to play more," said Dr. Herrity.

Read the rest here:
9/11 Search And Rescue Dog Gets Stem Cell Treatment

State: Second doctor's license restricted for performing stem cell treatment on patient who died

Dr. Konstantine K. Yankopolus

The state Department of Health restricted a second doctor's license for working under the direction of Dr. Zannos Grekos in performing a stem cell treatment and for falsifying a medical report after a patient died, according to the state order.

The emergency license restriction is against Dr. Konstantine K. Yankopolus, 3880 Colonial Blvd., Suite 2, Fort Myers, according to the order issued by the state health department late Monday.

The restriction only prohibits Yankopolus from doing anything with stem cells. After a career as an obstetrician/gynecologist, he is now in general practice.

"We attempted a life-saving procedure on a very sick patient and it didn't go well," Yankopolus said Monday night. "Our motivation was pure the patient had no other option."

The state's action comes on the heels of Grekos attorney last week issuing a statement that another doctor, and not his client, was involved in the treatment of a 77-year-old Indiana man who died March 2. Grekos attorney also denied that a stem cell treatment was performed, only liposuction.

The state health department suspended Grekos license after the death, saying Grekos violated an earlier restriction that he not to do anything with stem cells or bone marrow aspirate in his practice at 9500 Bonita Beach Road, Suite 310.

Lee County sheriff's authorities identified the man as Richard Poling, of Newburgh, Ind. The Sheriff's Office also is conducting a criminal probe.

Grekos has been under state scrutiny by state health regulators for well over a year when an earlier patient, a 66-year-old breast cancer patient, went to him for stem cell treatment in 2010 for neurological problems. She later fell, suffered severe brain damage and was taken off life support. After her death, the state ordered Grekos not to do anything with stem cells or bone marrow aspirate in his practice.

The restriction did not prohibit him from conducting educational seminars in the community about stem cell therapy or from arranging for patients to go for the treatment in the Dominican Republic.

More here:
State: Second doctor's license restricted for performing stem cell treatment on patient who died

Huntington's Disease – Stem Cell Therapy Potential

Editor's Choice Academic Journal Main Category: Huntingtons Disease Also Included In: Stem Cell Research Article Date: 19 Mar 2012 - 10:00 PDT

email to a friend printer friendly opinions

Current Article Ratings:

However, according to a study published March 15 in the journal Cell Stem Cell, a special type of brain cell created from stem cells could help restore the muscle coordination deficits that are responsible for uncontrollable spasms, a characteristic of the disease. The researchers demonstrated that movement in mice with a Huntington's-like condition could be restored.

Su-Chun Zhang, a University of Wisconsin-Madison neuroscientist and the senior author of the study, said:

In the study Zhang, who is an expert in creating various types of brain cells from human embryonic or induce pluripotent stem cells, and his team focused on GABA neurons. The degradation of GABA cells causes the breakdown of a vital neural circuit and loss of motor function in individuals suffering from Huntington's disease.

According to Zhang, GABA neurons generate a vital neurotransmitter, a chemical that helps support the communication network in the brain that coordinates movement.

Zhang and his team at the UW-Madison Waisman Center, discovered how to generate large quantities of GABA neurons from human embryonic stem cells. The team's goal was to determine whether these cells would safely integrate into the brain of a mouse model of Huntington's disease.

The researchers discovered that not only did the cells integrate, they were projected to the right target and were able to effectively restore the damaged communication network and restore motor function.

Zhang says that the results were astonishing, as GABA neurons reside in the basal ganglia, a part of the brain which plays a vital role in voluntary motor coordination. However, the GABA neurons exert their influence at a distance on cells in the midbrain via the circuit powered by the GABA neuron chemical neurotransmitter.

Follow this link:
Huntington's Disease - Stem Cell Therapy Potential

RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

NOKOMIS, Fla.--(BUSINESS WIRE)--

As global demand for innovative new stem-cell therapies grows by the day, Rainbow BioSciences (OTCBB:RBCC.OB - News) new agreement with n3D Biosciences could help to bring these therapies to market faster than ever before.

Stem cell therapies are becoming increasingly important to healthcare advancement around the world. Rising care delivery costs, worldwide population aging, and potential physician shortages are only three of the issues facing world healthcare providers. The cost to bring a new drug to market has soared to $1.3 billion, and there are now half as many drugs seeking approval as there were 15 years ago.

Rising costs and potential shortages have led to a boom in demand for stem cell therapies. These advanced treatments could soon help to ease costs and provide effective disease treatment, potentially improving patient outcomes and reducing health care costs. For that to happen, however, real challenges must be overcome. Translation of these therapies from the lab to the clinic is slow, and widespread implementation could be a decade away or more.

Thanks to n3Ds Bio-Assembler technology, however, the development timeline for many stem cell therapies could potentially be shortened significantly. The Bio-Assembler enables researchers to culture cells in three dimensions faster and more easily than ever before, streamlining testing and research.

On Thursday, RBCC announced the acquisition of an equity interest in n3D, a fully commercialized company with plans to sell the ground-breaking Bio-Assembler to labs and researchers all over the world. RBCC expects n3Ds value to grow considerably as word spreads about the game-changing technology.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ:CELG),Cardinal Health, Inc.(NYSE:CAH), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

Follow us on Twitter atwww.twitter.com/RBCCinfo.

About Rainbow BioSciences

See the original post:
RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster